K M Sanfilippo1, T F Wang2, B F Gage3, S Luo4, P Riedell3, K R Carson5. 1. Department of Medicine, Washington University School of Medicine Saint Louis, United States; Saint Louis Veterans Health Administration Medical Center, The Ohio State University Comprehensive Cancer Center, United States. Electronic address: ksanfili@dom.wustl.edu. 2. Department of Medicine, The Ohio State University Comprehensive Cancer Center, United States. 3. Department of Medicine, Washington University School of Medicine Saint Louis, United States. 4. Saint Louis Veterans Health Administration Medical Center, The Ohio State University Comprehensive Cancer Center, United States. 5. Department of Medicine, Washington University School of Medicine Saint Louis, United States; Saint Louis Veterans Health Administration Medical Center, The Ohio State University Comprehensive Cancer Center, United States.
Abstract
INTRODUCTION: Patients with non-Hodgkin lymphoma (NHL) have an increased risk of venous thromboembolism (VTE). Current risk-prediction models classify NHL as a single entity. We aimed to quantify the difference in VTE risk in follicular lymphoma (FL) versus diffuse large B cell lymphoma (DLBCL). METHODS: Using a prospective cohort study, we identified 2730 patients (2037 DLBCL; 693 FL) within the Veteran's Administration Central Cancer Registry. A competing risk model assessed the association between VTE risk and histology in the first year after NHL diagnosis. We assessed the effect of additional risk factors for VTE in NHL. RESULTS: In univariate analysis, DLBCL was associated with increased risk of VTE compared to FL in the first year after diagnosis; this association was no longer significant in adjusted analysis (adjusted hazard ratio (aHR) 1.52; 95% CI 0.97-2.40). Major risk factors for VTE included history of VTE before NHL diagnosis (aHR 4.73, p≤0.0001) and time period during chemotherapy administration (aHR 7.60, p≤0.0001). Additional risk factors included: stage III/IV disease (p=0.02), BMI≥30 (p=0.02), B-symptoms (p=0.02), and doxorubicin (p=0.04). The cumulative incidence of VTE was highest in the period following diagnosis and decreased over time for both histologies. CONCLUSION: DLBCL is associated with increased risk of VTE compared to FL. This risk is markedly attenuated when adjusting for additional risk factors. The strongest predictors for development of VTE included: time period during chemotherapy administration (especially doxorubicin) and history of VTE. This knowledge can assist clinicians in identifying NHL patients at high risk for VTE. Published by Elsevier Ltd.
INTRODUCTION:Patients with non-Hodgkin lymphoma (NHL) have an increased risk of venous thromboembolism (VTE). Current risk-prediction models classify NHL as a single entity. We aimed to quantify the difference in VTE risk in follicular lymphoma (FL) versus diffuse large B cell lymphoma (DLBCL). METHODS: Using a prospective cohort study, we identified 2730 patients (2037 DLBCL; 693 FL) within the Veteran's Administration Central Cancer Registry. A competing risk model assessed the association between VTE risk and histology in the first year after NHL diagnosis. We assessed the effect of additional risk factors for VTE in NHL. RESULTS: In univariate analysis, DLBCL was associated with increased risk of VTE compared to FL in the first year after diagnosis; this association was no longer significant in adjusted analysis (adjusted hazard ratio (aHR) 1.52; 95% CI 0.97-2.40). Major risk factors for VTE included history of VTE before NHL diagnosis (aHR 4.73, p≤0.0001) and time period during chemotherapy administration (aHR 7.60, p≤0.0001). Additional risk factors included: stage III/IV disease (p=0.02), BMI≥30 (p=0.02), B-symptoms (p=0.02), and doxorubicin (p=0.04). The cumulative incidence of VTE was highest in the period following diagnosis and decreased over time for both histologies. CONCLUSION: DLBCL is associated with increased risk of VTE compared to FL. This risk is markedly attenuated when adjusting for additional risk factors. The strongest predictors for development of VTE included: time period during chemotherapy administration (especially doxorubicin) and history of VTE. This knowledge can assist clinicians in identifying NHL patients at high risk for VTE. Published by Elsevier Ltd.
Authors: Lee Chun Park; Sook-young Woo; Seonwoo Kim; Hyejin Jeon; Young Hyeh Ko; Seok Jin Kim; Won Seog Kim Journal: Thromb Res Date: 2012-04-14 Impact factor: 3.944
Authors: Jennifer L Lund; Lene Sofie Østgård; Paolo Prandoni; Henrik Toft Sørensen; Peter de Nully Brown Journal: Thromb Res Date: 2015-09-05 Impact factor: 3.944
Authors: Martha L Louzada; Marc Carrier; Alejandro Lazo-Langner; Vi Dao; Michael J Kovacs; Timothy O Ramsay; Marc A Rodger; Jerry Zhang; Agnes Y Y Lee; Guy Meyer; Philip S Wells Journal: Circulation Date: 2012-06-07 Impact factor: 29.690
Authors: Ian W Flinn; Richard van der Jagt; Brad S Kahl; Peter Wood; Tim E Hawkins; David Macdonald; Mark Hertzberg; Yiu-Lam Kwan; David Simpson; Michael Craig; Kathryn Kolibaba; Samar Issa; Regina Clementi; Doreen M Hallman; Mihaela Munteanu; Ling Chen; John M Burke Journal: Blood Date: 2014-03-03 Impact factor: 22.113
Authors: Paul Poku Sampene Ossei; Isaac Kofi Owusu; Gerald Owusu-Asubonteng; Frank Ankobea-Kokroe; William Gilbert Ayibor; Nicholas Niako Journal: Clin Med Insights Circ Respir Pulm Med Date: 2020-10-13
Authors: Stefan Hohaus; Maria Chiara Tisi; Francesca Bartolomei; Annarosa Cuccaro; Elena Maiolo; Eleonora Alma; Francesco D'Alò; Silvia Bellesi; Elena Rossi; Valerio De Stefano Journal: Blood Cancer J Date: 2018-06-07 Impact factor: 11.037
Authors: Steven P Grover; Yohei M Hisada; Raj S Kasthuri; Brandi N Reeves; Nigel Mackman Journal: Arterioscler Thromb Vasc Biol Date: 2021-02-11 Impact factor: 8.311